WFM
VRTX icon

Wilmington Funds Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Wilmington Funds Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$727K Buy
7,683
+3,400
+79% +$238K 0.07% 262
2014
Q1 		$303K Hold
4,283
– – 0.03% 513
2013
Q4 		$318K Sell
4,283
-1,700
-28% -$118K 0.03% 542
2013
Q3 		$454K Hold
5,983
– – 0.04% 406
2013
Q2 		$478K Buy
+5,983
New +$441K 0.05% 387

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wilmington Funds Management's VRTX Position: Q2 2014 in Review

Wilmington Funds Management increased its Vertex Pharmaceuticals (VRTX) stake by 79% in Q2 2014, buying an estimated $238K and bringing the position to 7,683 shares worth $727K. The position accounts for 0.07% of the portfolio, ranked #262.

Wilmington Funds Management first reported a position in VRTX in Q2 2013 and has held it in 5 quarters since. 411 funds tracked by Wall St. Rank hold VRTX as of Q2 2014.

  • Wilmington Funds Management held 7,683 shares of Vertex Pharmaceuticals worth $727K as of Q2 2014.
  • Wilmington Funds Management bought 3,400 Vertex Pharmaceuticals shares in Q2 2014, an estimated $238K.
  • Vertex Pharmaceuticals made up 0.07% of Wilmington Funds Management's portfolio in Q2 2014, its #262 holding.
  • Wilmington Funds Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
  • 411 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.